Ranbaxy in-licenses asthma drug from Eurodrug Laboratories

By Lisa Kerner

Erie, Pa., May 17 - Ranbaxy Laboratories Ltd. reached an in-licensing agreement with the Netherlands-based Eurodrug Laboratories for the asthma product Doxophylline, a novel xanthine bronchodilator to be introduced in India under the brand name Synasma.

The drug, indicated for chronic bronchitis, asthma and chronic obstructive pulmonary disease, has been marketed by Eurodrug in Europe, Latin America, Korea, Philippines and Thailand.

"Synasma (Doxophylline) is yet another innovative asthma drug to be introduced in India for the first time by Ranbaxy," regional director Sanjeev I Dani said in the release.

"It is our strategic intent to in-license differentiated products for the Indian market in the post-patent era and this drug augments the company's position in the fast-growing asthma segment."

India has an estimated 15 million to 20 million asthmatic patients.

Ranbaxy is a generic pharmaceutical company based in Gurgaon, India

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.